Tags

Type your tag names separated by a space and hit enter

Mutations in type I collagen genes resulting in osteogenesis imperfecta in humans.
Acta Biochim Pol. 2002; 49(2):433-41.AB

Abstract

Osteogenesis imperfecta (OI), commonly known as "brittle bone disease", is a dominant autosomal disorder characterized by bone fragility and abnormalities of connective tissue. Biochemical and molecular genetic studies have shown that the vast majority of affected individuals have mutations in either the COL1A1 or COL1A2 genes that encode the chains of type I procollagen. OI is associated with a wide spectrum of phenotypes varying from mild to severe and lethal conditions. The mild forms are usually caused by mutations which inactivate one allele of COL1A1 gene and result in a reduced amount of normal type I collagen, while the severe and lethal forms result from dominant negative mutations in COL1A1 or COL1A2 which produce structural defects in the collagen molecule. The most common mutations are substitutions of glycine residues, which are crucial to formation and function of the collagen triple helix, by larger amino acids. Although type I collagen is the major structural protein of both bone and skin, the mutations in type I collagen genes cause a bone disease. Some reports showed that the mutant collagen can be expressed differently in bone and in skin. Since most mutations identified in OI are dominant negative, the gene therapy requires a fundamentally different approach from that used for genetic-recessive disorders. The antisense therapy, by reducing the expression of mutant genes, is able to change a structural mutation into a null mutation, and thus convert severe forms of the disease into mild OI type I.

Authors+Show Affiliations

Department of Medical Chemistry, Medical Academy of Białystok, Poland. angajko@amb.ac.bialystok.pl

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

12362985

Citation

Gajko-Galicka, Anna. "Mutations in Type I Collagen Genes Resulting in Osteogenesis Imperfecta in Humans." Acta Biochimica Polonica, vol. 49, no. 2, 2002, pp. 433-41.
Gajko-Galicka A. Mutations in type I collagen genes resulting in osteogenesis imperfecta in humans. Acta Biochim Pol. 2002;49(2):433-41.
Gajko-Galicka, A. (2002). Mutations in type I collagen genes resulting in osteogenesis imperfecta in humans. Acta Biochimica Polonica, 49(2), 433-41.
Gajko-Galicka A. Mutations in Type I Collagen Genes Resulting in Osteogenesis Imperfecta in Humans. Acta Biochim Pol. 2002;49(2):433-41. PubMed PMID: 12362985.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mutations in type I collagen genes resulting in osteogenesis imperfecta in humans. A1 - Gajko-Galicka,Anna, PY - 2002/10/5/pubmed PY - 2003/10/8/medline PY - 2002/10/5/entrez SP - 433 EP - 41 JF - Acta biochimica Polonica JO - Acta Biochim Pol VL - 49 IS - 2 N2 - Osteogenesis imperfecta (OI), commonly known as "brittle bone disease", is a dominant autosomal disorder characterized by bone fragility and abnormalities of connective tissue. Biochemical and molecular genetic studies have shown that the vast majority of affected individuals have mutations in either the COL1A1 or COL1A2 genes that encode the chains of type I procollagen. OI is associated with a wide spectrum of phenotypes varying from mild to severe and lethal conditions. The mild forms are usually caused by mutations which inactivate one allele of COL1A1 gene and result in a reduced amount of normal type I collagen, while the severe and lethal forms result from dominant negative mutations in COL1A1 or COL1A2 which produce structural defects in the collagen molecule. The most common mutations are substitutions of glycine residues, which are crucial to formation and function of the collagen triple helix, by larger amino acids. Although type I collagen is the major structural protein of both bone and skin, the mutations in type I collagen genes cause a bone disease. Some reports showed that the mutant collagen can be expressed differently in bone and in skin. Since most mutations identified in OI are dominant negative, the gene therapy requires a fundamentally different approach from that used for genetic-recessive disorders. The antisense therapy, by reducing the expression of mutant genes, is able to change a structural mutation into a null mutation, and thus convert severe forms of the disease into mild OI type I. SN - 0001-527X UR - https://www.unboundmedicine.com/medline/citation/12362985/Mutations_in_type_I_collagen_genes_resulting_in_osteogenesis_imperfecta_in_humans_ L2 - http://www.actabp.pl/pdf/2_2002/433.pdf DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.